Cargando…
Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals
Allergic asthma has traditionally been treated with inhaled and systemic glucocorticosteroids. A continuum of allergic fungal airways disease associated with Aspergillus fumigatus colonization and/or atopic immune responses that encompasses fungal asthma, severe asthma with fungal sensitization and...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861760/ https://www.ncbi.nlm.nih.gov/pubmed/36675906 http://dx.doi.org/10.3390/jof9010085 |
_version_ | 1784874922314563584 |
---|---|
author | Moss, Richard B. |
author_facet | Moss, Richard B. |
author_sort | Moss, Richard B. |
collection | PubMed |
description | Allergic asthma has traditionally been treated with inhaled and systemic glucocorticosteroids. A continuum of allergic fungal airways disease associated with Aspergillus fumigatus colonization and/or atopic immune responses that encompasses fungal asthma, severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis is now recognized along a phenotypic severity spectrum of T2-high immune deviation lung disease. Oral triazoles have shown clinical, anti-inflammatory and microbiologic efficacy in this setting; in the future inhaled antifungals may improve the therapeutic index. Humanized monoclonal antibody biologic agents targeting T2-high disease also show efficacy and promise of improved control in difficult cases. Developments in these areas are highlighted in this overview. |
format | Online Article Text |
id | pubmed-9861760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98617602023-01-22 Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals Moss, Richard B. J Fungi (Basel) Perspective Allergic asthma has traditionally been treated with inhaled and systemic glucocorticosteroids. A continuum of allergic fungal airways disease associated with Aspergillus fumigatus colonization and/or atopic immune responses that encompasses fungal asthma, severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis is now recognized along a phenotypic severity spectrum of T2-high immune deviation lung disease. Oral triazoles have shown clinical, anti-inflammatory and microbiologic efficacy in this setting; in the future inhaled antifungals may improve the therapeutic index. Humanized monoclonal antibody biologic agents targeting T2-high disease also show efficacy and promise of improved control in difficult cases. Developments in these areas are highlighted in this overview. MDPI 2023-01-06 /pmc/articles/PMC9861760/ /pubmed/36675906 http://dx.doi.org/10.3390/jof9010085 Text en © 2023 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Moss, Richard B. Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals |
title | Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals |
title_full | Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals |
title_fullStr | Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals |
title_full_unstemmed | Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals |
title_short | Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals |
title_sort | severe fungal asthma: a role for biologics and inhaled antifungals |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861760/ https://www.ncbi.nlm.nih.gov/pubmed/36675906 http://dx.doi.org/10.3390/jof9010085 |
work_keys_str_mv | AT mossrichardb severefungalasthmaaroleforbiologicsandinhaledantifungals |